Scott Alexander analyzes the potential role of psychopharmacology in the FTX crash, discussing medications used by SBF and others, and their possible effects on decision-making. Longer summary

Scott Alexander discusses the psychopharmacology aspects of the FTX crash, focusing on the medications Sam Bankman-Fried (SBF) and other FTX employees may have been taking. He examines claims about SBF's use of Emsam (selegiline), modafinil, and other stimulants, explaining their effects and potential risks. Scott also critiques the actions of FTX's company psychiatrist and discusses the broader implications of stimulant use in high-pressure work environments. The post ends with Scott's personal anecdote about testifying as an expert witness. Shorter summary

Scott Alexander analyzes online drug ratings, finding patients prefer older antidepressants while doctors prefer newer ones, and explores potential explanations for this paradox. Longer summary

Scott Alexander analyzes patient ratings of antidepressants from online databases, finding that older drugs like MAOIs are rated higher than newer ones. He then compares this to doctor ratings, discovering a negative correlation between patient and doctor preferences. The post explores possible explanations for these paradoxical results, including confounding factors and the hypothesis that newer antidepressants may actually be less effective. Scott extends the analysis to other drug classes, finding the negative doctor-patient correlation holds broadly, while the preference for older drugs is specific to psychiatric medications. Shorter summary